Evaluation of cryptolepine and huperzine derivatives as lead compounds towards new agents for the treatment of human African trypanosomiasis

Natural Product Communications

Volumn 4, Issue 2, 2009, Pages 193-198

  Oluwafemi, Awotunde J ^a   Okanla, Emmanuel O ^a   Camps, Pelayo ^b   Muñoz Torrero, Diego ^b   Mackey, Zachary B ^c   Chiang, Peter K ^d   Seville, Scott ^e   Wright, Colin W ^e  

^a UNIVERSITY OF ILORIN   (Nigeria)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Pharmadyn Inc   (United States)

^e UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Cryptolepine; Cryptolepis sanguinolenta; Huperzia serrata; Huperzine; Huprine; Trypanosomiasis

Indexed keywords

11 CHLOROCRYPTOLEPINE; 2 CHLOROCRYPTOLEPINE; 2 FLUOROCRYPTOLEPINE; 2,7 DIBROMOCRYPTOLEPINE; 7 BROMOCRYPTOLEPINE; 7 BROMOCRYPTOLEPINE HYDROCHLORIDE; 8 CHLOROCRYPTOLEPINE; CRYPTOLEPINE; CRYPTOLEPINE DERIVATIVE; HUPERZINE A; THIOMERSAL; UNCLASSIFIED DRUG; ANTITRYPANOSOMAL AGENT; INDOLE ALKALOID; QUINOLINE DERIVATIVE; SESQUITERPENE;

AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARASITEMIA; RAT; REFERENCE VALUE; SINGLE DRUG DOSE; SURVIVAL TIME; TRYPANOSOMA BRUCEI; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CRYPTOLEPIS; DRUG ADMINISTRATION ROUTE; HUMAN; HUPERZIA;

CRYPTOLEPIS SANGUINOLENTA; HUPERZIA SERRATA; RATTUS; TRYPANOSOMA BRUCEI;

ANIMALS; CRYPTOLEPIS; DRUG ADMINISTRATION ROUTES; HUMANS; HUPERZIA; INDOLE ALKALOIDS; MOLECULAR STRUCTURE; QUINOLINES; RATS; SESQUITERPENES; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 66849127677     PISSN: 1934578X     EISSN: 15559475     Source Type: Journal    
DOI: 10.1177/1934578x0900400205     Document Type: Article

References (15)

1. Delespaux V, de Koning HP. (2007) Drugs and drug resistance in African trypanosomiasis. Drug Research Updates, 10, 30-50. (Pubitemid 46636383)
2. http://www.who.org
3. Welburn SC, Coleman PG, Maudlin I, Fevre EM, Odiit M, Eisler MC. (2006) Crisis, what crisis? Control of Rhodesian sleeping sickness. Trends in Parasitology, 22, 123-128. (Pubitemid 43290227)
4. Wright CW, Addae-Kyereme J, Breen AG , Brown JE, Cox MF, Croft SL, Gokcek Y, Kendrick H, Phillips RM, Pollet, P. (2001) Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. Journal of Medicinal Chemistry, 44, 3187-3194. (Pubitemid 32862349)
5. Onyeibor O, Croft SL, Dodson HI, Feiz-Haddad M, Kendrick H, Millington NJ, Parapini S, Phillips RM, Seville S, Shnyder SD, Taramelli D, Wright, CW. (2005) Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. Journal of Medicinal Chemistry, 48, 2701-2709. (Pubitemid 40516460)
6. Ma, X, Tan C, Zhu D, Gang DR, Xiao P. (2007) Huperzine A from Huperzia species - An ethnopharmacological review. Journal of Ethnopharmacology, 113, 15-34. (Pubitemid 47077860)
7. Lisgarten JN, Coll M, Portugal J, Wright CW, Aymami J. (2002) The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nature Structural Biology, 9, 57-60. (Pubitemid 34049181)
8. Bonjean K, de Pauw-Gillet MC, Defresne MP, Colson P, Houssier C, Dassoneville L, Bailly C, Greimers R, Wright C, Quetin-Leclercq J, Tits M, Angenot L. (1998) The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry, 37, 5136-5146.
9. Rojas M, Wright CW, Pina B, Portugal J (2008) Genome-wide expression profiling of cryptolepine-induced toxicity in Saccharomyces cerevisiae. Antimicrobial Agents and Chemotherapy, 52, 3844-3850.
10. Camps P, Cussack B, Mallender WD, El Achab R, Morral J, Munoz-Torrero D, Rosenberry TL. (2000) Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Molecular Pharmacology, 57, 409-417.
11. Camps P, Contreras J, Font-Bardia M, Morral J, Munoz-Torrero D, Solans X. (1998) Enantioselective synthesis of tacrinehuperzine A hybrids. Preparative chiral MPLC separation of their racemic mixtures and absolute configuration assigments by X-ray diffraction analysis. Tetrahedron: Asymmetry, 9, 835-849.
12. Camps P, El Achab R, Gorbig DM, Morral J, Munoz-Torrero D, Badia A, Banos JE, Vivas NM, Barril X, Orozco M, Luque FJ. (1999) Synthesis, in vitro pharmacology and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry, 42, 3227-3242.
13. Mackey ZB, Baca AM, Mallari JP, Apsel B, Shelat A, Hansell J, Chiang PK, Wolff B, Guy KR, Williams J, McKerrow JH. (2006) Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chemical and Biological Drug Design 67, 355-363.
14. Zweygarth E, Kaminsky R. (1991) Evaluation of DL-α- difluoromethylornithine against susceptible and drug-resistant Trypanosoma brucei brucei. Acta Tropica, 48, 223-232.
15. Daniel AD, Dadah AT, Kaleejaiye JO, Dalhatu AD. (1993) Prevalence of bovine trypanosomiasis in Gongola state of Northern Nigeria. Revue d' Elevage Medecine Veterinaire des Pays Tropicaux (Paris), 46, 571-574.